Tag: anti-BCMA


FDA Grants Orphan Drug Designation to BCMA-Targeted TriTAC HPN217 for Myeloma

  Jan 13 2021 Tagged MM, anti-BCMA

The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct (TriTAC) as treatment for patients with multiple myeloma, according to an announcement from Harpoon Therapeutics, Inc.

Visit website